About
fMRI biomarkers
Areas of Focus
Categories
DiagnosticsBoston & New England
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
12
As Collaborator
1
Total Enrollment
799
By Phase
PHASE2: 7PHASE2/PHASE3: 2PHASE1: 1
By Status
COMPLETED: 6AVAILABLE: 3ACTIVE_NOT_RECRUITING: 2WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05299658Lead Sponsor
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
PHASE2Active, not recruiting
40 participants
Started: Nov 13, 2021 · Completed: Aug 31, 2025
NCT04610138Lead Sponsor
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
PHASE2Completed
296 participants
Started: Jun 1, 2021 · Completed: Oct 20, 2022
NCT04626921Lead Sponsor
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
PHASE2/PHASE3Completed
55 participants
Started: Oct 22, 2020 · Completed: Sep 6, 2023
NCT04414345Collaborator
HEALEY ALS Platform Trial - Regimen C CNM-Au8
PHASE2/PHASE3Completed
161 participants
Started: Jul 30, 2020 · Completed: Mar 7, 2023
NCT03843710Lead Sponsor
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)
PHASE2Withdrawn
Started: Mar 31, 2020 · Completed: Mar 31, 2022
Funding History (1)
D
Nov 22, 2021
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...